Purdue Pharma v. Accord Healthcare – Federal Circuit Affirms (Case 25-1060)
Purdue Pharma brought an infringement action against Accord Healthcare, Ltd. centred on US11304908B2, a patent covering tamper-resistant dosage forms. The Court of Appeals for the Federal Circuit, after 601 days, entered a one-line order: AFFIRMED — leaving the lower decision intact.
Federal Circuit upholds lower ruling in Purdue–Accord dosage-form dispute
Purdue Pharma, holder of US11304908B2 directed to tamper-resistant dosage forms, pursued an infringement action against Accord Healthcare, Ltd. The appeal — Case No. 25-1060 — was docketed at the Court of Appeals for the Federal Circuit on 15 October 2024 and arose from an underlying infringement action. Accord Healthcare was represented by McAndrews, Held & Malloy Ltd., with attorneys Alejandro Menchaca, Ben Mahon, and Rajendra A. Chiplunkar on record.
The Federal Circuit closed the case on 8 June 2026, issuing a terse dispositive order: 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.' The recorded Basis of Termination is 'Appeal Dismissed'; the docket order states 'AFFIRMED.' These two characterisations appear in the record as-is — the specific procedural relationship between them is not further explained in the available data.
The 601-day appellate timeline is consistent with a fully briefed Federal Circuit proceeding. No settlement terms, licensing arrangements, or cost awards are disclosed in the public record. What drove the Federal Circuit's affirmance — claim construction, validity, or another ground — is not detailed in the available case data.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 601 days
601 days from filing to Federal Circuit disposition
US11304908B2 — Tamper-Resistant Pharmaceutical Dosage Forms
Any company developing, manufacturing, or seeking to commercialise tamper-resistant or abuse-deterrent pharmaceutical dosage forms — particularly generic manufacturers pursuing ANDA approval — should treat US11304908B2 as a priority FTO target following the Federal Circuit's affirmance. The affirmed claim scope now carries heightened precedential weight, making it essential to confirm whether a proposed formulation falls within or clear of the asserted claims before committing to regulatory or commercial milestones.
Official order — verbatim text
The Federal Circuit's order — 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED' — is a merits affirmance, confirming that the court found no reversible error in the lower tribunal's resolution of the infringement action. The recorded Basis of Termination is 'Appeal Dismissed'; the docket order states 'AFFIRMED.' Both are reported as-is from the record — the specific procedural relationship between them is not further explained in the available case data.
Federal Circuit affirms: what the ruling means for both parties
What 'AFFIRMED' means at Federal Circuit level
An affirmance by the Court of Appeals for the Federal Circuit means the court found no reversible error in the decision below. The lower tribunal's ruling is left intact in its entirety. The Federal Circuit does not retry facts; it reviews legal conclusions de novo and factual findings for clear error, making an affirmance a significant endorsement of the reasoning applied below.
No reversible error foundPurdue Pharma's patent survives appellate challenge
For Purdue Pharma, the affirmance preserves whatever rights the lower decision conferred regarding US11304908B2. The patent covering tamper-resistant dosage forms remains on the enforcement footing established by the court below. Competitors seeking to design around or challenge this patent now face an appellate record confirming the lower ruling's validity.
Patent position preservedAccord Healthcare's appellate avenue exhausted at this level
For Accord Healthcare, the Federal Circuit affirmance closes the primary appellate path at the circuit level. Further review would require a petition for certiorari to the US Supreme Court — a high-bar, discretionary avenue. The specific consequences for Accord's product programme depend on the underlying district court relief, which is not detailed in the available record.
Further review requires certiorariStrengthened patent raises the bar for tamper-resistant formulation entry
A Federal Circuit affirmance on a pharmaceutical dosage-form patent typically signals heightened risk for generic or competing manufacturers operating in the tamper-resistant formulation space. Companies with products or pipeline assets touching the technology claimed in US11304908B2 should treat this outcome as a prompt to review freedom-to-operate positions. The higher appellate bar following affirmance makes future challenge more difficult.
Higher bar for future IPRFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Purdue Pharma | Company | /Search in Eureka ↗ |
| Defendant | Accord Healthcare, Ltd. | Company | /Search in Eureka ↗ |
| Defendant counsel | Alejandro Menchaca | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Ben Mahon | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Rajendra A. Chiplunkar | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant law firm | McAndrews, Held & Malloy Ltd. | Law Firm | Representing Accord Healthcare, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in tamper-resistant pharmaceutical formulation IP
Forward-looking patent and innovation intelligence derived from Purdue Pharma v. Accord Healthcare and the broader tamper-resistant dosage-form technology landscape.
Purdue Pharma's tamper-resistant dosage-form filing activity
US11304908B2 is one data point in what is likely a broader Purdue Pharma filing strategy around abuse-deterrent and tamper-resistant formulations. Mapping continuation, divisional, and continuation-in-part applications from the same family can reveal the breadth of claim coverage Purdue is building — and where enforcement campaigns may next emerge for generic entrants.
Purdue portfolio depthFiling trends in abuse-deterrent pharmaceutical formulations
The abuse-deterrent and tamper-resistant formulation space has seen sustained patent activity since FDA issued its guidance on opioid products. Tracking filing trends by assignee, claim type (physical barrier, chemical antagonist, prodrug), and application date can help R&D teams identify where the technology frontier is moving — and which claim categories remain contested or uncrowded.
Formulation filing trendsAccord Healthcare's IP position in controlled-release formulations
As a generic pharmaceutical manufacturer defending infringement claims, Accord Healthcare's own patent filings — if any — in the controlled-release or tamper-resistant space can reveal its R&D direction and defensive IP strategy. Understanding Accord's portfolio helps competitors and partners assess whether it is building proprietary formulation technology or relying primarily on FTO clearance pathways.
Generic manufacturer IP strategyAdjacent R&D opportunities near US11304908B2 claim scope
The claim scope of US11304908B2 defines a boundary around which design-around opportunities may exist. Adjacent technologies — such as alternative physical deterrent mechanisms, novel excipient combinations, or digital monitoring integrated with dosage forms — may represent white-space areas where new filings could achieve freedom to operate while addressing the same unmet clinical need for abuse deterrence.
Design-around white spaceSimilar Federal Circuit appeals in tamper-resistant pharmaceutical patent disputes
Explore Federal Circuit appeals involving tamper-resistant or abuse-deterrent dosage-form patents and infringement actions against generic pharmaceutical manufacturers.
What this case signals for the tamper-resistant pharma IP landscape
A Federal Circuit affirmance on tamper-resistant dosage-form patents sharpens enforcement risk across the controlled-release pharmaceutical sector.
Affirmed dosage-form patents carry enhanced deterrent value
When the Federal Circuit affirms a pharmaceutical formulation patent, the resulting record raises the litigation risk calculus for every generic or branded competitor operating near that claim scope. Companies with tamper-resistant or controlled-release products in development or on the market should treat this affirmance as a signal to audit their FTO exposure against US11304908B2 without delay.
ANDA filers in tamper-resistant formulations face a tighter legal environment
Accord Healthcare's posture is consistent with ANDA-related paragraph IV litigation, a common pathway for generic pharmaceutical market entry. The Federal Circuit's affirmance reinforces the strength of Purdue's patent position in this space and suggests that challengers using similar formulation strategies should re-examine invalidity and non-infringement arguments before advancing to district court or the PTAB.
Purdue v Accord — key questions answered
The Court of Appeals for the Federal Circuit entered an order on 8 June 2026 stating 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.' The recorded Basis of Termination is 'Appeal Dismissed.' Both characterisations appear in the available record; their precise procedural relationship is not further explained in the public case data.
The patent at issue is US11304908B2 (application number US17/027222), covering tamper-resistant dosage forms. The underlying infringement action concerned Accord Healthcare's alleged infringement of this Purdue Pharma patent in the controlled-release pharmaceutical product category.
A Federal Circuit affirmance closes the primary appellate path for Accord Healthcare at the circuit level. The lower decision stands without modification. Further review would require a petition for certiorari to the US Supreme Court — a high-bar, discretionary process. The specific impact on Accord's product programme depends on the district court relief granted below, which is not detailed in the available record.
Accord Healthcare was represented by McAndrews, Held & Malloy Ltd. The attorneys of record for Accord were Alejandro Menchaca, Ben Mahon, and Rajendra A. Chiplunkar. No plaintiff law firm or agent data is recorded in the available case information for Purdue Pharma.
Yes. A Federal Circuit affirmance reinforces the enforceability of US11304908B2 and raises the litigation risk for any manufacturer developing or commercialising tamper-resistant dosage forms. Companies with ANDA filings or development programmes in this space should conduct a freedom-to-operate analysis against the affirmed claims and monitor Purdue Pharma's related patent family for further enforcement risk.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.